Drug Registration: A Necessary but Not Sufficient Condition for Good Quality Drugs
A Preliminary Analysis of Twelve Countries

There is a tacit assumption amongst healthcare workers that all drugs of the same therapeutic type, whether innovator brands, generic brands, or a variety of copies of the product, are interchangeable. While there may be concern that some countries' products are more likely to be counterfeited, if one assumes the product is genuine, then the assumption holds that the product will work.

But anecdotal reports suggest that, even when counterfeits and otherwise obviously degraded or grossly substandard products are identified and removed from any sample set, quality problems remain for some products. Given that western countries source so many drug ingredients from abroad, for instance, up to 80% of the active ingredients in U.S. drugs are now made overseas, news reports of nefarious activity have made westerners wary of drugs produced in emerging economies. A recent Pew Trusts poll indicated that 54% and 70% of Americans distrusted drugs sourced respectively in India and China. But it is not acceptable in international trade law to boycott products based on suspicion alone, nor is it prudent since many drugs made in emerging economies are demonstrably fine and are certainly cheaper than innovator brands.

This working paper is the first part of a project looking at various characteristics, including product variability, of essential drugs in developing and mid-income countries. The publication that will follow this paper will assess actual drug variability; this working paper addresses what is probably a significant driver of drug quality--the legislative environment, and in particular, the registration process in which medicines are made and, more critically, sold. . . .

Read this full paper as an Adobe Acrobat PDF.

Roger Bate is the Legatum Fellow in Global Prosperity at AEI. Emily Putze is a research assistant at AEI. Alexandra McPherson is at the Boston University School of Public Health. Sarah Naoshy is at the Boston University School of Public Health. Lorraine Mooney is a researcher, editor, economist and medical demographer at Africa Fighting Malaria.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate

What's new on AEI

Rebuilding American defense: A speech by Governor Bobby Jindal
image Smelling liberal, thinking conservative
image Stopping Ebola before it turns into a pandemic
image All too many reasons for pessimism about Europe
AEI on Facebook
Events Calendar
  • 20
    MON
  • 21
    TUE
  • 22
    WED
  • 23
    THU
  • 24
    FRI
Monday, October 20, 2014 | 2:00 p.m. – 3:30 p.m.
Warfare beneath the waves: The undersea domain in Asia

We welcome you to join us for a panel discussion of the undersea military competition occurring in Asia and what it means for the United States and its allies.

Tuesday, October 21, 2014 | 8:30 a.m. – 10:00 a.m.
AEI Election Watch 2014: What will happen and why it matters

AEI’s Election Watch is back! Please join us for two sessions of the longest-running election program in Washington, DC. 

Wednesday, October 22, 2014 | 1:00 p.m. – 2:30 p.m.
What now for the Common Core?

We welcome you to join us at AEI for a discussion of what’s next for the Common Core.

Thursday, October 23, 2014 | 10:00 a.m. – 11:00 a.m.
Brazil’s presidential election: Real challenges, real choices

Please join AEI for a discussion examining each candidate’s platform and prospects for victory and the impact that a possible shift toward free-market policies in Brazil might have on South America as a whole.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.